Medicinova Inc (MNOV): Geoffrey Obrien , Vice President of Medicinova Inc sold 3,300 shares on Jul 5, 2016. The Insider selling transaction was reported by the company on Jul 7, 2016 to the Securities and Exchange Commission. The shares were sold at $8.00 per share for a total value of $26,400.00 , the company said in a SEC Form 4 Filing.
Shares of MediciNova (MNOV) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.05 points or -0.63% at $7.91 with 1,22,954 shares getting traded. Post opening the session at $7.87, the shares hit an intraday low of $7.8 and an intraday high of $8 and the price vacillated in this range throughout the day. The company has a market cap of $255 M and the number of outstanding shares has been calculated to be 3,22,58,195 shares. The 52-week high of MediciNova is $10.16 and the 52-week low is $2.62.
MediciNova Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS) amyotrophic lateral sclerosis (ALS) and substance dependence and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.